NEW YORK, NY--(Marketwire - December 1, 2008) - Daxor Corporation (AMEX: DXR), a medical
instrumentation and biotechnology company, today announced that The Board
of Directors has voted to declare a special year-end dividend of $1.00 per
share. The dividend will be paid to shareholders of record as of December
12, 2008. The dividend will be paid on Tuesday, December 30, 2008.
The Company previously paid quarterly dividends of $0.25 per share in 2008
on August 27th and November 26th. Prior to 2008, the Company last paid a
dividend in 1996.
The Company is continuing to build-out its manufacturing facilities in Oak
Ridge, Tennessee which is comprised of two separate 10,000 sq. ft.
buildings.
There are ongoing studies on the utilization of the BVA-100 Blood Volume
Analyzer in Critical Care Medicine which are nearing completion and will be
ready for submission for publication in peer reviewed medical journals.
Preliminary reports have indicated that as much as 30% of patients in
intensive care units who receive transfusions or are denied transfusions
may be inappropriately treated. The standard surrogate tests such as the
hematocrit or hemoglobin tests have been shown in a number of independent
studies to be inaccurate in gauging the true blood volume status of a
patient. This may result in serious complications, including the death of
the patient. The BVA-100 Blood Volume Analyzer provides a measurement of
the patient's blood volume to within 98% accuracy.
The Company continues its R&D efforts to work on the development of an
automated total body albumin analyzer. Albumin is a major protein within
the blood that can be used to help support the circulation in patients with
acute blood loss. Up to the present time there has been no available
instrument to measure the total amount of this important protein within the
body which has resulted in significant under utilization of albumin
administration in situations where it could help prevent collapsed
circulation.
For more information regarding Daxor Corporation's BVA-100 Blood Volume
Analyzer, visit Daxor's website www.Daxor.com, or contact Stephen Feldschuh
(COO) at 212-330-8515, stephen@daxor.com or Diane Meegan (Investor
Relations) at 212-330-8512, dmeegan@daxor.com.